Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
60%(3 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
4
80%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

NCT02178722
completedphase_1

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

NCT02318277
completedphase_1

A Dose-escalation Study in Subjects With Advanced Malignancies

NCT01195311
completedphase_1

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT02118285
completedphase_2

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

NCT01822691

Clinical Trials (5)

Showing 5 of 5 trials
NCT02178722Phase 1

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Completed
NCT02318277Phase 1

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Completed
NCT01195311Phase 1

A Dose-escalation Study in Subjects With Advanced Malignancies

Completed
NCT02118285Phase 1

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Completed
NCT01822691Phase 2

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5